Results 181 to 190 of about 117,631 (302)

Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan

British Journal of Haematology, EarlyView.
ALT and ferritin were adverse prognostic markers enabling risk stratification in adult systemic chronic active Epstein–Barr virus disease (sCAEBV). In hydroa vacciniforme lymphoproliferative disorder (HV‐LPD), Epstein–Barr virus (EBV) infection of CD4+ cells was associated with progression to sCAEBV.
Aika Fuseya, Masahide Yamamoto, Miwako Nishio, Ryo Kitabayashi, Akihiro Hirakawa, Hiroshi Yasui, Yoshihiro Umezawa, Keisuke Tanaka, Hayato Tamai, Yu Uemura, Kumi Oshima, Fumiaki Sano, Takehiko Mori, Ryuji Koike, Shouichi Ohga, Ayako Arai   +15 more
wiley   +1 more source

The use of Janus kinase inhibitors to treat noninfectious uveitis. [PDF]

Eye (Lond)
Beckman M, Srivastava SK, Lowder CY, Baynes K, Lowe A, Sharma S.   +5 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Management of Pregnancy in Women with Inflammatory Bowel Disease: Positioning Janus Kinase Inhibitors Within Current Evidence. [PDF]

Curr Issues Mol Biol
Colacurci D, Pellegrino R, Lamart A, Staiano D, De Costanzo I, Izzo M, Imperio G, Landa F, Scamardella G, Di Lella E, Federico A, Sarno L, Gravina AG.   +12 more
europepmc   +1 more source

Janus Kinase Family [PDF]

, 2020
openaire   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series. [PDF]

Case Rep Dermatol
Zhao G, Liu Y, Ni J, Song Z.
europepmc   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source